Gilead announces interim Phase 2 data for idelalisib showing response in refractory indolent non-Hodgkin’s lymphoma
Results from Phase 2 study...
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
List view / Grid view
Results from Phase 2 study...
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
Gilead Sciences announced interim results from a single-arm, open-label Phase…
17 June 2013 | By Gilead Sciences, Inc.
Gilead Sciences announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib...